Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors

Journal of Infectious Diseases

Volumn 209, Issue 6, 2014, Pages 845-854

  Keating, Sheila M ^a,b   Heitman, John D ^a   Wu, Shiquan ^a   Deng, Xutao ^a,b   Stramer, Susan L ^c   Kuhns, Mary C ^d   Mullen, Carolyn ^d   Norris, Philip J ^a,b   Busch, Michael P ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMERICAN RED CROSS   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

acute infection; chemokine; cytokine; hepatitis B virus; immunity; vaccination

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; VIRUS DNA;

ADAPTIVE IMMUNITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; HEPATITIS B; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; VACCINATION; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ACUTE INFECTION; CHEMOKINE; CYTOKINE; HEPATITIS B VIRUS; IMMUNITY; VACCINATION;

ACUTE DISEASE; BLOOD DONORS; CLUSTER ANALYSIS; CYTOKINES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; LONGITUDINAL STUDIES; VACCINATION; VIRAL LOAD; VIRUS REPLICATION;

EID: 84895737359     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit563     Document Type: Article

References (24)

1. World Health Organization. Hepatitis B. Global Alert and Response. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index5. html. Accessed 31 October 2013.
2. Whalley SA, Murray JM, Brown D, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001; 193:847-54.
3. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: Nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006; 10:77-91.
4. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364:236-47.
5. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43:788-98.
6. Webster GJ, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 2000; 32:1117-24.
7. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004; 101: 2129-34.
8. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Gut 2012; 61:1754-64.
9. Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004; 114:701-12.
10. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719-33.
11. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137:1289-300.
12. Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993; 262:369-70.
13. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1. Immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1-31.
14. Seed CR, Jones NT, Pickworth AM, Graham WR. Two cases of asymptomatic HBV "vaccine breakthrough" infection detected in blood donors screened for HBV DNA. Med J Aust 2012; 196:651-2.
15. Gerlich WH. Breakthrough of hepatitis B virus escapes mutants after vaccination and virus reactivation. J Clin Virol 2006; 36(Suppl 1): S18-22.
16. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41.
17. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: Results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-6.
18. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84.
19. Abushady EA, Gameel MM, Klena JD, Ahmed SF, Abdel-Wahab KS, Fahmy SM. HBV vaccine efficacy and detection and genotyping of vaccine asymptomatic breakthrough HBV infection in Egypt. World J Hepatol 2011; 3:147-56.
20. Mamik MK, Ghorpade A. Src homology-2 domain-containing protein tyrosine phosphatase (SHP) 2 and p38 regulate the expression of chemokine CXCL8 in human astrocytes. PLoS One 2012; 7:e45596.
21. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: Analyses of the window period and kinetics of HBV DNA. Vox Sang 2005; 88:77-86.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289-300.
23. Yoshikawa A, Gotanda Y, Minegishi K, et al. Lengths of hepatitis B viremia and antigenemia in blood donors: Preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007; 47:1162-71.
24. Feeney SA, McCaughey C,Watt AP, et al. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti- HBc negative patient. J Med Virol 2013; 85:597-601.